GlaxoSmithKline PLC

GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
  • TickerGSK
  • ISINGB0009252882
  • ExchangeLondon Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom

Analysts

Damien Conover

Clinton’s Proposed Drug Plan Doesn’t Change the Pricing Power for Innovative Drugs

We don’t expect any significant fair value estimate changes in the drug group based on Democratic presidential candidate Hillary Clinton’s disclosed drug pricing plan targeting unjustified price increases for older drugs. While passage of the plan in Congress would be very uncertain, if the plan were to take shape, we expect less innovative generic drugs and older branded drugs to be the focus of price controls. Further, we believe the core element of patent protection supporting drug prices is...

Damien Conover

Clinton’s Proposed Drug Plan Doesn’t Change the Pricing Power for Innovative Drugs

We don’t expect any significant fair value estimate changes in the drug group based on Democratic presidential candidate Hillary Clinton’s disclosed drug pricing plan targeting unjustified price increases for older drugs. While passage of the plan in Congress would be very uncertain, if the plan were to take shape, we expect less innovative generic drugs and older branded drugs to be the focus of price controls. Further, we believe the core element of patent protection supporting drug prices is...

ValuEngine Rating and Forecast Report for GSK

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and useful report available. ValuEngine`s three models: Valuation Model, Forecast Model and Ratings Model are incorporated to give you a well-rounded analysis from three different perspectives. Consensus EPS trend and Earnings Surprise statistics provide additional insights. Also, ValuEngine recommendation, Forecast analysis, Past performance, Evaluation and rankings, Comparison to industry, Comparison with peers, Analyst opinions, EPS consensus expectations, Company profil...

Naresh Chouhan

Shape Shifter?

GSK continues to face an uncertain future but we believe there is scope for a turnaround through an asset swap which would strengthen the Consumer business and reduce exposure to the ailing Pharma division. The new CEO could be the catalyst for such change and if she executes on an asset swap we believe the shares would re-rate materially. However, in the absence of our ‘fantasy’ M&A scenario we see continued downgrades to consensus and see limited upside to the current share price. ‘Get out of Jail Card’ – We have devised a potential asset swap that GSK could engage in with Pfizer which woul...

Damien Conover

Pricing pressure and branded competition to Glaxo's key respiratory drugs are weighing on growth.

We don’t expect any significant fair value estimate changes in the drug group based on Democratic presidential candidate Hillary Clinton’s disclosed drug pricing plan targeting unjustified price increases for older drugs. While passage of the plan in Congress would be very uncertain, if the plan were to take shape, we expect less innovative generic drugs and older branded drugs to be the focus of price controls. Further, we believe the core element of patent protection supporting drug prices is...

GlaxoSmithKline plc - December 2016 (LTM): Peer Snapshot

Peer Snapshot: GlaxoSmithKline plc - December 2016 (LTM) 13 April 2017 (in US millions) FYE Dec-14 FYE Dec-15 LTM Dec-16 FYE Dec-14 FYE Dec-15 LTM Dec-16 FYE Dec-14 FYE Dec-15 LTM Dec-16

GlaxoSmithKline plc: Delayed Launch of Generic Advair Is Credit Positive for GSK

CORPORATES ISSUER COMMENT 11 May 2017 Contacts Knut Slatten 33-1-5330-1077 VP-Senior Analyst [email protected] Yasmina Serghini 33-1-5330-1064 Associate Managing Director [email protected] GlaxoSmithKline plc Delayed Launch of Generic Advair Is Credit Positive for GSK On 11 May 2017, the US Food and Drug Administration (FDA) issued a complete response letter (CRL) to Hikma Pharmace

For GSK, Delay of Generic Advair Is Credit Positive

    ISSUER COMMENT  CORPORATES    MAY 15, 2017    For GSK, Delay of Generic Advair Is   Credit Positive  From  Credit Outlook   On Thursday, the US Food and Drug Administration (FDA) issued a complete response letter  (CRL) t

GlaxoSmithKline plc - March 2017 (LTM): Peer Snapshot

Peer Snapshot: GlaxoSmithKline  plc - March 2017 (LTM) 26 May 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Mar-17 FYE Dec-14 FYE Dec-15 LTM Dec-16 FYE Dec-14 FYE Dec-15 LTM

GlaxoSmithKline plc: Update to Discussion of Key Credit Factors

CORPORATES CREDIT OPINION 15 June 2017 Update RATINGS GlaxoSmithKline plc Domicile United Kingdom Long Term Rating A2 Type LT Issuer Rating Outlook Negative Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Knut Slatten 33-1-5330-1077 VP-Senior Analyst [email protected] Yasmina

Damien Conover

Clinton’s Proposed Drug Plan Doesn’t Change the Pricing Power for Innovative Drugs

We don’t expect any significant fair value estimate changes in the drug group based on Democratic presidential candidate Hillary Clinton’s disclosed drug pricing plan targeting unjustified price increases for older drugs. While passage of the plan in Congress would be very uncertain, if the plan were to take shape, we expect less innovative generic drugs and older branded drugs to be the focus of price controls. Further, we believe the core element of patent protection supporting drug prices is...

Damien Conover

Clinton’s Proposed Drug Plan Doesn’t Change the Pricing Power for Innovative Drugs

We don’t expect any significant fair value estimate changes in the drug group based on Democratic presidential candidate Hillary Clinton’s disclosed drug pricing plan targeting unjustified price increases for older drugs. While passage of the plan in Congress would be very uncertain, if the plan were to take shape, we expect less innovative generic drugs and older branded drugs to be the focus of price controls. Further, we believe the core element of patent protection supporting drug prices is...

Naresh Chouhan

Shape Shifter?

GSK continues to face an uncertain future but we believe there is scope for a turnaround through an asset swap which would strengthen the Consumer business and reduce exposure to the ailing Pharma division. The new CEO could be the catalyst for such change and if she executes on an asset swap we believe the shares would re-rate materially. However, in the absence of our ‘fantasy’ M&A scenario we see continued downgrades to consensus and see limited upside to the current share price. ‘Get out of Jail Card’ – We have devised a potential asset swap that GSK could engage in with Pfizer which woul...

Damien Conover

Pricing pressure and branded competition to Glaxo's key respiratory drugs are weighing on growth.

We don’t expect any significant fair value estimate changes in the drug group based on Democratic presidential candidate Hillary Clinton’s disclosed drug pricing plan targeting unjustified price increases for older drugs. While passage of the plan in Congress would be very uncertain, if the plan were to take shape, we expect less innovative generic drugs and older branded drugs to be the focus of price controls. Further, we believe the core element of patent protection supporting drug prices is...

Damien Conover

Pricing pressure and branded competition to Glaxo's key respiratory drugs are weighing on growth.

We don’t expect any significant fair value estimate changes in the drug group based on Democratic presidential candidate Hillary Clinton’s disclosed drug pricing plan targeting unjustified price increases for older drugs. While passage of the plan in Congress would be very uncertain, if the plan were to take shape, we expect less innovative generic drugs and older branded drugs to be the focus of price controls. Further, we believe the core element of patent protection supporting drug prices is...

1 director bought

A director at GlaxoSmithKline bought 3,600 shares at 20.875USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Eric Monnier

Top Picks Q2 Healthcare: From five names down to three

The least we can say about Q1 2018 is that it was another tough quarter for healthcare in general with few exceptions across the sector, despite early activity on the M&A front with Sanofi announcing the acquisitions of Bioverativ and Ablynx in January. This was not enough to prevent the sector from underperforming the general indices by 1.4pp (-6% in absolute terms). We assume this is mainly the reflection of shy 2018 guidance on average from most companies suggesting in the end another transition year with very limited growth, most of which coming from the positive impact of the US tax refor...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Michael Foundoukidis
  • Nicolas David
  • Salma Bouraoui
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 26/10/2018

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Baptiste Lebacq
  • Christophe Chaput
  • Delphine Brault
  • Emira Sagaama
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Léopold Authié
  • Matthias Desmarais
  • Michael Foundoukidis
  • Olfa Taamallah
  • Olivier Lebrun
  • Pierre Tegner
  • Rémi Adam
  • Samantha Jeary
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 26/10/2018

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Baptiste Lebacq
  • Christophe Chaput
  • Delphine Brault
  • Emira Sagaama
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Léopold Authié
  • Matthias Desmarais
  • Michael Foundoukidis
  • Olfa Taamallah
  • Olivier Lebrun
  • Pierre Tegner
  • Rémi Adam
  • Samantha Jeary
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/26/2018

...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Michael Foundoukidis
  • Nicolas David
  • Salma Bouraoui
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 10/26/2018 Date Performance since listing Date Performance since listing

...

Ahmed Ben Salem ...
  • Antoine Boivin-Champeaux
  • Christophe-Raphaël Ganet
  • Igor Kim
  • Jean Sassus
  • Jean-Baptiste Rouphael
  • Martial Descoutures
  • Pierre Corby
  • Roland Pfaender
  • Steven Gould
  • Valentin Pernet
  • Yan Derocles
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 01/11/2018

...

ValuEngine Rating and Forecast Report for GSK

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and useful report available. ValuEngine`s three models: Valuation Model, Forecast Model and Ratings Model are incorporated to give you a well-rounded analysis from three different perspectives. Consensus EPS trend and Earnings Surprise statistics provide additional insights. Also, ValuEngine recommendation, Forecast analysis, Past performance, Evaluation and rankings, Comparison to industry, Comparison with peers, Analyst opinions, EPS consensus expectations, Company profil...

ValuEngine Rating and Forecast Report for GSK

ValuEngine Rating and Forecast Report for GSK

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

Dominic Rose ...
  • Naresh Chouhan

Revenue Downgrade Cycle Almost Over

Persistent revenue downgrades have led to investor concern around future analyst forecasts, particularly for new drugs. Our analysis shows that the causes of the sector revenue downgrades have been largely driven by Primary Care launches in the US. More importantly, we show that the downside risk to future new product forecasts has fallen materially. We argue that if forecasts are now more accurate, the recent Pharma sell-off creates a good entry point.

Dominic Rose ...
  • Naresh Chouhan

New Asthma Drugs Set to Sell $10bn

Five new drugs will drive the Severe Uncontrolled Asthma market from $4bn today to $10bn by 2023. Our bottom-up model shows that biologic drug penetration could almost double by 2023. We see AZN and Sanofi as material winners in the space and show that consensus is likely too low on Tezepelumab, Fasenra & Dupixent. Fasenra is already winning against Nucala (GSK), the P3 Dupixent asthma data has gone underappreciated and consensus models just $200m for Teze in 2023 in AZN numbers.

MarketLine Department

Actelion Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Actelion Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Actelion Ltd since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highligh...

MarketLine Department

Vectura Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Vectura Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Vectura Group plc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Ke...

MarketLine Department

F. Hoffmann-La Roche Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's F. Hoffmann-La Roche Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by F. Hoffmann-La Roche Ltd since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive a...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 04/05/2017

Sir Andrew Witty will be stepping down as CEO with effect from 31 March 2017 and will be succeeded by Emma Walmsley. Dr Patrick Vallance joined the Board in his role as President, R&D on 1 January 2017. Item 2: Approve the Remuneration Report. The remuneration structure is unsatisfactory. Variable remuneration has the potential to be excessive and the actual awards exceeded guidelines. Item 15: Re-appoint the Auditor. PricewaterhouseCoopers LLP (PwC) have been the Group

Expert Corporate Governance Service (ECGS)

GlaxoSmithKline - AGM 08 May 2019

The AGM is followed by an EGM to be held at 15:30 in the same location.  AGM Item 2: Approve the Remuneration Report The remuneration structure is unsatisfactory.  The main concern is the potential for excessive incentive pay with a maximum of 850% of base salary.  In addition, the use of qualitative criteria exceeds guidelines and accelerated vesting is possible.  The quantum for the year is also considered excessive.  We recommend shareholders oppose.  EGM Item 1: To approve the transaction between GlaxoSmithKline Consumer Healthcare Holdings Ltd and Pfizer Inc The Company is seeking sha...

Louis-Clément AZAIS d'UHART

Analyse court terme - GLAXOSMITHKLINE : Consolidation

Notre précédent avis était neutre. Nous sommes maintenant négatif avec un objectif à 1578 p et un niveau d'invalidation à 1677 p. Une consolidation intermédiaire interrompt temporairement la tendance haussière.

Louis-Clément AZAIS d'UHART

Short term view - GLAXOSMITHKLINE : Consolidation

Our previous opinion was neutral. We turn negative with a target at 1578 p and an invalidation level at 1677 p. An intermediate consolidation is interrupting the rally.

Louis-Clément AZAIS d'UHART

Short term view - GLAXOSMITHKLINE : Pull-back

In our previous short term analysis (17/11/2016), we were negative. We remain negative with a target at 1462 p and an invalidation level at 1562 p. The bearish trend is interrupted by a pull-back. Arguments : - The support has been breached. - Prices are pulling back to the...

Louis-Clément AZAIS d'UHART

Analyse court terme - GLAXOSMITHKLINE : Pull-back

Lors de notre dernière analyse court terme (17/11/2016), nous avions opté pour un avis négatif. Nous restons négatif avec un objectif à 1462 p et un niveau d'invalidation à 1562 p. La tendance baissière est interrompue par un pull-back. Arguments : - Le support est enfoncé....

Valérie GASTALDY

Medium term view - GLAXOSMITHKLINE : A double top has just been triggered.

The previous significant trough has been broken. The trend now is neutral. Should prices move back above this level, we would face a false signal.Arguments :- The support has been breached.- A double top has just been triggered.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch